 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...6061626364656667686970...7475» |
- || LKA651 / Novartis, MorphoSys
Trial primary completion date: A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Jun 11, 2015
P1, N=72, Not yet recruiting, Sponsor: Alcon Research
Trial primary completion date: Jun 2016 --> Dec 2016
- |||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial primary completion date: Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (clinicaltrials.gov) - Jun 11, 2015
P3, N=475, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Jan 2016 --> Oct 2016
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date, Combination therapy: Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (clinicaltrials.gov) - Jun 11, 2015
P4, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2016 --> Oct 2016 Trial primary completion date: Jan 2017 --> Jan 2018
- || Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Trial primary completion date: Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD (clinicaltrials.gov) - Jun 11, 2015
P4, N=110, Active, not recruiting, Sponsor: University of Cologne
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Dec 2013 --> Dec 2016
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial termination: CONSTELLATION: Efficacy and Safety of Lucentis (clinicaltrials.gov) - Jun 11, 2015
P3, N=31, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2013 --> Dec 2016 N=155 --> 31 | Recruiting --> Terminated; Study was prematurely discontinued as it was unethical to continue based on a change in ranibizumab (RFB) marketing authorization.
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Trial initiation date: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (clinicaltrials.gov) - Jun 6, 2015
P3, N=649, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=155 --> 31 | Recruiting --> Terminated; Study was prematurely discontinued as it was unethical to continue based on a change in ranibizumab (RFB) marketing authorization. Recruiting --> Active, not recruiting | Initiation date: Oct 2004 --> Dec 2013
- ||||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Combination therapy, Monotherapy: To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema (clinicaltrials.gov) - Jun 4, 2015
P4, N=60, Not yet recruiting, Sponsor: The University of Hong Kong
- |||||||||| Rayoqta (abicipar pegol) / Molecular Partners
New P3 trial: SEQUOIA: Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jun 4, 2015
P3, N=900, Not yet recruiting, Sponsor: Allergan
- |||||||||| Rayoqta (abicipar pegol) / Molecular Partners
New P3 trial: CDER: A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jun 4, 2015
P3, N=900, Not yet recruiting, Sponsor: Allergan
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: TIDE AMD: Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Jun 4, 2015
P4, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Initiation date: Oct 2004 --> Dec 2013 Not yet recruiting --> Recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Enrollment closed, Combination therapy, Monotherapy: EVEREST II: Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (clinicaltrials.gov) - Jun 3, 2015
P4, N=321, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New trial: Photobiomodulation for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - May 29, 2015
P=N/A, N=0, Withheld, Sponsor: [Redacted]
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Surgery: OCTOPUS: Use of Ranibizumab With Mitomycin C During Trabeculectomy (clinicaltrials.gov) - May 28, 2015
P=N/A, N=30, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Metastases: Lucentis in Advanced Macular Degeneration (clinicaltrials.gov) - May 27, 2015
P2, N=20, Completed, Sponsor: Steven R. Sanislo
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Fovista (pegpleranib) / Roche, Astellas
Enrollment closed, Combination therapy: Phase 2A Open Label Safety Study of Fovista (clinicaltrials.gov) - May 26, 2015
P2a, N=100, Active, not recruiting, Sponsor: Ophthotech Corporation
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: aiRTo-PDR: 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial (clinicaltrials.gov) - May 19, 2015
P3, N=200, Not yet recruiting, Sponsor: JUNYAN ZHANG
- Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates (clinicaltrials.gov) - May 19, 2015
P1/2, N=30, Not yet recruiting, Sponsor: South Coast Retina Center; Carson, McBeath, Boswell, Inc.
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide (clinicaltrials.gov) - May 19, 2015
P1, N=20, Recruiting, Sponsor: Soll Eye
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Fumena (vorolanib) / Tyrogenex
Enrollment closed, Trial primary completion date: Pilot Study of X-82 in Patients With Wet AMD (clinicaltrials.gov) - May 19, 2015
P1/2, N=20, Active, not recruiting, Sponsor: Tyrogenex
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Jan 2015
- ||||| Fovista (pegpleranib) / Roche, Astellas
Enrollment closed, Combination therapy, Monotherapy: A Phase 3 Safety and Efficacy Study of Fovista (clinicaltrials.gov) - May 13, 2015
P3, N=622, Active, not recruiting, Sponsor: Ophthotech Corporation
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Jan 2015 Recruiting --> Active, not recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: POLARIS: Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy (clinicaltrials.gov) - May 8, 2015
P=N/A, N=911, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jan 2015
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: FVF4154s: ERG/EOG Study in AMD Patients Treated With Ranibizumab (clinicaltrials.gov) - May 8, 2015
P=N/A, N=10, Completed, Sponsor: Retina Center, Minnesota
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Jan 2015 Active, not recruiting --> Completed
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME (clinicaltrials.gov) - May 5, 2015
P2, N=100, Recruiting, Sponsor: Arshad Khanani
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial termination: Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II) (clinicaltrials.gov) - May 2, 2015
P2, N=6, Terminated, Sponsor: Jumper, J. Michael, M.D.
Active, not recruiting --> Recruiting Completed --> Terminated; Study was terminated due to low enrollment
- | Rayoqta (abicipar pegol) / Molecular Partners
Trial completion: A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Apr 30, 2015
P2, N=25, Completed, Sponsor: Allergan
Completed --> Terminated; Study was terminated due to low enrollment Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial termination: Ranibizumab and the Risk of Arterial Thromboembolic Events (clinicaltrials.gov) - Apr 29, 2015
P4, N=380, Terminated, Sponsor: Ural State Medical Academy
Active, not recruiting --> Completed Completed --> Terminated; The study was terminated under the political pressure of the Federal Security Service of the Russian Federation (FSB) and the Russian Society of Cardiology
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=300, Recruiting, Sponsor: NJ Retina
Completed --> Terminated; The study was terminated under the political pressure of the Federal Security Service of the Russian Federation (FSB) and the Russian Society of Cardiology Trial primary completion date: Oct 2014 --> Jun 2016
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. (clinicaltrials.gov) - Apr 21, 2015
P=N/A, N=300, Recruiting, Sponsor: NJ Retina
Trial primary completion date: Oct 2014 --> Jun 2016 Trial primary completion date: Mar 2016 --> Jun 2016
- acrizanib (LHA510) / Novartis
Trial primary completion date: LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration (clinicaltrials.gov) - Apr 20, 2015
P2, N=60, Recruiting, Sponsor: Alcon, a Novartis Company
Trial primary completion date: Mar 2016 --> Jun 2016 Trial primary completion date: Mar 2016 --> Nov 2015
- ||| Lucentis (ranibizumab) / Roche, Novartis
New trial: Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis (clinicaltrials.gov) - Apr 17, 2015
P=N/A, N=300, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial primary completion date: Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis (clinicaltrials.gov) - Apr 16, 2015
P=N/A, N=30, Completed, Sponsor: University of British Columbia
Trial primary completion date: Mar 2016 --> Nov 2015 Recruiting --> Completed | N=60 --> 30 | Trial primary completion date: Jul 2013 --> Oct 2013
- || LKA651 / Novartis, MorphoSys
Trial primary completion date: A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema (clinicaltrials.gov) - Apr 14, 2015
P1, N=72, Not yet recruiting, Sponsor: Alcon Research
Recruiting --> Completed | N=60 --> 30 | Trial primary completion date: Jul 2013 --> Oct 2013 Trial primary completion date: Dec 2016 --> Jun 2016
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Enrollment change, Trial primary completion date: Bevacizumab Versus Ranibizumab for Diabetic Retinopathy (clinicaltrials.gov) - Apr 14, 2015
P3, N=30, Completed, Sponsor: Ursula Schmidt-Erfurth, M.D.
Trial primary completion date: Dec 2016 --> Jun 2016 Suspended --> Completed | N=60 --> 30 | Trial primary completion date: Sep 2012 --> Mar 2013
- |||| Fumena (vorolanib) / Tyrogenex
Enrollment open, Monotherapy, Head-to-Head: X-82 to Treat Age-related Macular Degeneration (clinicaltrials.gov) - Apr 14, 2015
P2, N=132, Recruiting, Sponsor: Tyrogenex
Suspended --> Completed | N=60 --> 30 | Trial primary completion date: Sep 2012 --> Mar 2013 Not yet recruiting --> Recruiting
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: STAR: OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab (clinicaltrials.gov) - Apr 14, 2015
P2, N=30, Recruiting, Sponsor: McMaster University
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Feb 2016
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date, Combination therapy, Monotherapy: Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - Apr 14, 2015
P2, N=40, Recruiting, Sponsor: Medical University of Vienna
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: Jun 2014 --> Jun 2015
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) (clinicaltrials.gov) - Apr 14, 2015
P3, N=282, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Dec 2015 --> Apr 2016
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Camellia: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) (clinicaltrials.gov) - Apr 14, 2015
P3, N=252, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Dec 2015 --> Mar 2016
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Efficacy and Safety of Lucentis (clinicaltrials.gov) - Apr 14, 2015
P4, N=60, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Mar 2016 N=80 --> 60
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients (clinicaltrials.gov) - Apr 14, 2015
P3, N=380, Recruiting, Sponsor: Novartis Pharmaceuticals
N=80 --> 60 Not yet recruiting --> Recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. (clinicaltrials.gov) - Apr 14, 2015
P3, N=183, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: RELATE: Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions (clinicaltrials.gov) - Apr 3, 2015
P1/2, N=81, Completed, Sponsor: Peter A Campochiaro, MD
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Apr 2015
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: RaTAPDR: 25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China (clinicaltrials.gov) - Mar 31, 2015
P2/3, N=120, Recruiting, Sponsor: JUNYAN ZHANG
Active, not recruiting --> Completed | Trial primary completion date: Nov 2013 --> Apr 2015 Not yet recruiting --> Recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial primary completion date, Head-to-Head: DIVERSE: Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema (clinicaltrials.gov) - Mar 27, 2015
P4, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2015 --> Aug 2017
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: The TURF Study: Study for Recalcitrant Age Related Macular Degeneration (clinicaltrials.gov) - Mar 26, 2015
P4, N=46, Completed, Sponsor: David M. Brown, M.D.
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2015 --> Aug 2017 Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2014
- Izervay (avacincaptad pegol intravitreal solution) / Astellas
New P2 trial: A Study to Establish the Safety and Tolerability of Zimura (clinicaltrials.gov) - Mar 25, 2015
P2, N=5, Recruiting, Sponsor: Ophthotech Corporation
- ||||| LMG324 / Novartis, Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Mar 25, 2015
P1/2, N=106, Not yet recruiting, Sponsor: Alcon Research
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration (clinicaltrials.gov) - Mar 24, 2015
P4, N=17, Completed, Sponsor: Institut de la Macula y la Retina
Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Oct 2014 Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Mar 2012
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: T-REX: Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab (clinicaltrials.gov) - Mar 14, 2015
P3, N=60, Active, not recruiting, Sponsor: Charles C Wykoff, PhD, MD
Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Mar 2012 Trial primary completion date: Jan 2015 --> Feb 2017
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept (clinicaltrials.gov) - Mar 14, 2015
P=N/A, N=25, Active, not recruiting, Sponsor: The Cleveland Clinic
Trial primary completion date: Jan 2015 --> Feb 2017 Trial primary completion date: Jun 2014 --> Jun 2016